The Long Run with Luke Timmerman

Est. audience

2,600

Apple rating

4.7 from 127

Cadence

Every two weeks

Latest

2026-10-23

By

Timmerman Report

Based on

12 recent episodes

• Covers: Interviews with biotech newsmakers covering drug development, life sciences entrepreneurship, emerging therapies, and industry challenges.
• For: Biotech founders, life sciences executives, researchers, and healthcare venture capitalists.
• Best for: Professionals and investors building or funding commercial biotechnology and pharmaceutical ventures.
• Skip if: Consumers seeking general health advice or casual medical news.

Start with

• Ep212: Tim Shannon on Creating Targeted Protein Degraders as Medicines: Explores building and investing in targeted protein degrader biotechnology companies.
• Ep210: Cameron Turtle on Long-Lasting Antibodies for Immune Disorders: Covers executive strategy in developing novel antibody therapies for immune disorders.
• Ep202: Becky Pferdehirt on Reimagining Science for the AI Era: Discusses integrating artificial intelligence advances into modern life sciences and biology.

Visit

Summarised by AI from 12 recent episodes. Audience estimate and Apple rating from Podscan, checked 2026-11-03; treat the estimate as a guide and ask the show for its own numbers. Prices are not included. Report a mistake.